Key points from article :
A new screening test could discover ovarian cancers up to 2 years earlier than available tests.
Involves screening a blood sample for abnormal levels of a biomarker made up of four proteins.
At stage one of Epithelial Ovarian Cancer (EOC), there is a 90 per cent chance of five-year survival.
But if diagnosed at stage three or four the survival rate reduces to 22 per cent.
Need to test it in a wider sample set to be before they can recommend it to general population.
Analysed blood samples from 80 individuals across a seven-year period.
Study by Cancer Research UK, published in the journal Nature.
